DK3998285T3 - Bindingsmolekyler til cd38 og pd-l1 - Google Patents
Bindingsmolekyler til cd38 og pd-l1 Download PDFInfo
- Publication number
- DK3998285T3 DK3998285T3 DK21214273.1T DK21214273T DK3998285T3 DK 3998285 T3 DK3998285 T3 DK 3998285T3 DK 21214273 T DK21214273 T DK 21214273T DK 3998285 T3 DK3998285 T3 DK 3998285T3
- Authority
- DK
- Denmark
- Prior art keywords
- binding molecules
- molecules
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305350 | 2016-03-25 | ||
| EP17713672.8A EP3433273B1 (en) | 2016-03-25 | 2017-03-27 | Binding molecules to cd38 and pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3998285T3 true DK3998285T3 (da) | 2025-04-14 |
Family
ID=55646510
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21214273.1T DK3998285T3 (da) | 2016-03-25 | 2017-03-27 | Bindingsmolekyler til cd38 og pd-l1 |
| DK17713672.8T DK3433273T3 (da) | 2016-03-25 | 2017-03-27 | Binding af molekyler til cd38 og pd-l1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17713672.8T DK3433273T3 (da) | 2016-03-25 | 2017-03-27 | Binding af molekyler til cd38 og pd-l1 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11505616B2 (da) |
| EP (2) | EP3433273B1 (da) |
| JP (2) | JP7529401B2 (da) |
| KR (1) | KR102361412B1 (da) |
| CN (2) | CN109476741B (da) |
| AU (1) | AU2017236183B2 (da) |
| CA (1) | CA3022143A1 (da) |
| DK (2) | DK3998285T3 (da) |
| ES (2) | ES2906639T3 (da) |
| FI (1) | FI3998285T3 (da) |
| HU (2) | HUE070697T2 (da) |
| PL (2) | PL3433273T3 (da) |
| PT (2) | PT3433273T (da) |
| RU (1) | RU2764201C2 (da) |
| SG (1) | SG11201808289SA (da) |
| WO (1) | WO2017162890A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3433273T (pt) * | 2016-03-25 | 2022-02-21 | Biomunex Pharmaceuticals | Moléculas de ligação a cd38 e pd-l1 |
| SG11201809316XA (en) | 2016-04-28 | 2018-11-29 | Biomunex Pharmaceuticals | Bispecific antibodies targeting egfr and her2 |
| KR102589422B1 (ko) | 2017-01-09 | 2023-10-13 | 바이오뮤넥스 파마슈티컬스 | 다중특이적 항체를 제조하기 위한 폴리펩티드 링커 |
| KR20240125061A (ko) | 2017-03-27 | 2024-08-19 | 바이오뮤넥스 파마슈티컬스 | 안정적인 다중특이적 항체 |
| CN111819198A (zh) * | 2017-12-28 | 2020-10-23 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) |
| EA202091053A1 (ru) * | 2018-01-15 | 2020-12-03 | Ай-Маб Биофарма Юэс Лимитед | Модифицированные c- и ch1-домены |
| MA52212A (fr) | 2018-03-30 | 2021-02-17 | Merus Nv | Anticorps multivalent |
| KR20210091714A (ko) * | 2018-10-17 | 2021-07-22 | 이뮤놈 인코포레이티드 | 엑소좀-표적 이중 특이적 항체 |
| UA128001C2 (uk) * | 2018-12-21 | 2024-03-06 | Ф. Хоффманн-Ля Рош Аг | Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули |
| AU2019412561A1 (en) | 2018-12-24 | 2021-08-12 | Sanofi | Multispecific binding proteins with mutant Fab domains |
| US20240239912A1 (en) * | 2020-04-10 | 2024-07-18 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted reduction of activated immune cells |
| JP2022045530A (ja) * | 2020-09-09 | 2022-03-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ－１標的化ｉｌ－２変異体免疫サイトカインとヒトｐｄ－ｌ１に対する抗体との併用療法 |
| US20240228588A1 (en) * | 2021-01-11 | 2024-07-11 | Adimab, Llc | Variant ch1 domains and variant cl domains engineered for preferential chain pairing and multi-specific antibodies comprising the same |
| JPWO2023238949A1 (da) | 2022-06-10 | 2023-12-14 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP2003531588A (ja) * | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| TW201120210A (en) * | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| EP2655624B1 (en) | 2010-12-23 | 2017-11-29 | Biogen MA Inc. | Linker peptides and polypeptides comprising same |
| BR112013023918A2 (pt) | 2011-03-25 | 2016-12-13 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural |
| EP2543680A1 (en) | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| WO2014028776A1 (en) | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| US10047163B2 (en) * | 2013-02-08 | 2018-08-14 | Abbvie Stemcentrx Llc | Multispecific constructs |
| JP2016538275A (ja) | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造 |
| EP3699195A3 (en) * | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| ES2936810T3 (es) | 2014-05-16 | 2023-03-22 | Pfizer | Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| WO2016172485A2 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| PT3433273T (pt) * | 2016-03-25 | 2022-02-21 | Biomunex Pharmaceuticals | Moléculas de ligação a cd38 e pd-l1 |
| SG11201809316XA (en) | 2016-04-28 | 2018-11-29 | Biomunex Pharmaceuticals | Bispecific antibodies targeting egfr and her2 |
| WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| KR102589422B1 (ko) | 2017-01-09 | 2023-10-13 | 바이오뮤넥스 파마슈티컬스 | 다중특이적 항체를 제조하기 위한 폴리펩티드 링커 |
| KR20240125061A (ko) | 2017-03-27 | 2024-08-19 | 바이오뮤넥스 파마슈티컬스 | 안정적인 다중특이적 항체 |
| AU2018334886B2 (en) | 2017-09-22 | 2025-06-26 | WuXi Biologics Ireland Limited | Novel bispecific polypeptide complexes |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| GB201814562D0 (en) | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| GB201913079D0 (en) | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
-
2017
- 2017-03-27 PT PT177136728T patent/PT3433273T/pt unknown
- 2017-03-27 AU AU2017236183A patent/AU2017236183B2/en active Active
- 2017-03-27 JP JP2019501761A patent/JP7529401B2/ja active Active
- 2017-03-27 PL PL17713672T patent/PL3433273T3/pl unknown
- 2017-03-27 CN CN201780028279.6A patent/CN109476741B/zh active Active
- 2017-03-27 ES ES17713672T patent/ES2906639T3/es active Active
- 2017-03-27 KR KR1020187030790A patent/KR102361412B1/ko active Active
- 2017-03-27 WO PCT/EP2017/057220 patent/WO2017162890A1/en not_active Ceased
- 2017-03-27 US US16/088,181 patent/US11505616B2/en active Active
- 2017-03-27 ES ES21214273T patent/ES3023551T3/es active Active
- 2017-03-27 HU HUE21214273A patent/HUE070697T2/hu unknown
- 2017-03-27 EP EP17713672.8A patent/EP3433273B1/en active Active
- 2017-03-27 RU RU2018137419A patent/RU2764201C2/ru active
- 2017-03-27 DK DK21214273.1T patent/DK3998285T3/da active
- 2017-03-27 EP EP21214273.1A patent/EP3998285B1/en active Active
- 2017-03-27 FI FIEP21214273.1T patent/FI3998285T3/fi active
- 2017-03-27 HU HUE17713672A patent/HUE057657T2/hu unknown
- 2017-03-27 CA CA3022143A patent/CA3022143A1/en active Pending
- 2017-03-27 PL PL21214273.1T patent/PL3998285T3/pl unknown
- 2017-03-27 PT PT212142731T patent/PT3998285T/pt unknown
- 2017-03-27 DK DK17713672.8T patent/DK3433273T3/da active
- 2017-03-27 CN CN202310140318.9A patent/CN116284428A/zh active Pending
- 2017-03-27 SG SG11201808289SA patent/SG11201808289SA/en unknown
-
2022
- 2022-05-25 JP JP2022085095A patent/JP2022116166A/ja active Pending
- 2022-11-17 US US18/056,279 patent/US12528877B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3998285T3 (da) | Bindingsmolekyler til cd38 og pd-l1 | |
| IL261942A (en) | Bcma binding molecules and methods of use thereof | |
| IL263730A (en) | Binding molecules binding pd-l1 and lag-3 | |
| DK3328419T3 (da) | Pd-1-bindingsmolekyler og fremgangsmåder til anvendelse deraf | |
| DK3265575T3 (da) | Cd20-bindende molekyler og anvendelser deraf | |
| DK3116909T3 (da) | Antistofmolekyler til lag-3 og anvendelser deraf | |
| IL256416B (en) | Multispecific antigen-binding molecules and uses thereof | |
| IL266464A (en) | Binding of specific molecules to asct2 and their use | |
| DK3303379T3 (da) | Tigit-bindende midler og anvendelser deraf | |
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| DK3303265T3 (da) | Sammensætning indeholdende n-(n-butyl)-thiophosphortriamid-additionsprodukter og reaktionsprodukter | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| GB201612520D0 (en) | Binding molecules | |
| DK3097122T3 (da) | Antistoffer, der binder beta-klotho-domæne 2, og fremgangsmåder til anvendelse deraf | |
| IL262519A (en) | Binding molecules specific for fcgamma riia and uses thereof | |
| ZA201803841B (en) | Binding molecules specific for asct2 and uses thereof | |
| DK3105250T3 (da) | Multispecifikke iga-bindingsmolekyler | |
| IL258956A (en) | Compositions and methods for tumor transduction | |
| IL261653A (en) | Ilt7 binding molecules and methods of using the same | |
| DK3128997T3 (da) | Bindingmolekyler specifikke for il-21 og anvendelser deraf | |
| DK3417058T3 (da) | Sortase-modificerede molekyler og anvendelser deraf | |
| DK3303384T3 (da) | Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf | |
| EP3774922A4 (en) | BINDING MOLECULES INVOLVING CELLS | |
| DK3369208T3 (da) | System og fremgangsmåde til aflytningssikret godkendelse og kryptering | |
| DK3245204T3 (da) | Små molekyler til behandling af primær cancer og cancermetastase |